This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Actavis Leads the Way

NEW YORK (TheStreet) -- Some financial people do not really look at all the good things drug companies do. Instead, they focus on the creative destruction that happens when new replaces the old.

Think of all the popular brand names of the last decade: Rogaine, Plavix, Cymbalta, Oxycontin, Celebrex. It's a long list of exclusive money-making home runs now generic also-rans starring with a different label at a pharmacy shelf near you.

While lots of analysts like to pay attention to the pipelines full of miracle drugs of tomorrow, some companies do quite well with the miracle drugs of yesterday -- the generics.

Let's look at one: Actavis (ACT - Get Report).

The past 15 months have been a dog fight for supremacy among three sectors: pharmaceutical, biotech and Internet. At the start of the new year, pharmaceuticals emerged at the top of my leader board.

Data from Best Stocks Now App

One pharmaceutical that has performed and continues to perform quite well is Actavis. It has been a Gunderson Best Stock Now for quite some time and continues to be.

Data from Best Stocks Now App

Headquartered in New Jersey, ACT is a $31 billion large-cap company that develops, manufactures and distributes generic and branded drugs for hypertension, elevated cholesterol, contraception and pain. It is  currently working on a generic NuvaRing, a contraceptive.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ACT $297.05 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs